loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Pazopanib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Pazopanib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    Also known as: 635702-64-6, Pazopanib hcl, Votrient, Pazopanib (hydrochloride), Armala, Unii-33y9anm545
    Molecular Formula
    C21H24ClN7O2S
    Molecular Weight
    474.0  g/mol
    InChI Key
    MQHIQUBXFFAOMK-UHFFFAOYSA-N
    FDA UNII
    33Y9ANM545
    Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride
    2.1.2 InChI
    InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
    2.1.3 InChI Key
    MQHIQUBXFFAOMK-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    33Y9ANM545
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Gw 780604

    2. Gw 786034b

    3. Gw-780604

    4. Gw-786034b

    5. Gw780604

    6. Gw786034b

    7. Pazopanib

    8. Votrient

    2.3.2 Depositor-Supplied Synonyms

    1. 635702-64-6

    2. Pazopanib Hcl

    3. Votrient

    4. Pazopanib (hydrochloride)

    5. Armala

    6. Unii-33y9anm545

    7. Pazopanib Monohydrochloride

    8. Pazopanib Hcl (gw786034 Hcl)

    9. Gw786034b

    10. Gw-786034b

    11. Pazopanib (as Hydrochloride)

    12. Gw786034 (hydrochloride)

    13. 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride

    14. Chebi:71217

    15. 33y9anm545

    16. S1035

    17. 5-((4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide Hydrochloride

    18. 5-((4-((2,3-dimethyl-2h-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide Monohydrochloride

    19. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide Hydrochloride

    20. 5-{4-[(2,3-dimethyl-2h-indazol-6-yl)-methyl-amino]-pyrimidin-2-ylamino}-2-methyl-benzenesulfonamide Hydrochloride

    21. Benzenesulfonamide, 5-((4-((2,3-dimethyl-2h-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, Monohydrochloride

    22. Patorma

    23. Gw786034 Hcl

    24. Votrient Hcl

    25. Votrient (tn)

    26. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide Hydrochloride

    27. Pazopanib Hydrochloride [usan:jan]

    28. Mls004774147

    29. Schembl159487

    30. Pazopanib Hydrochloride- Bio-x

    31. Pazopanib Hydrochloride [usan]

    32. Chembl1201733

    33. Dtxsid70212956

    34. Ex-a956

    35. Pazopanib Hcl (gw786034 )

    36. Bcp02203

    37. Pazopanib Hydrochloride (jan/usan)

    38. Pazopanib Hydrochloride [mi]

    39. Mfcd12546138

    40. Nsc737754

    41. Pazopanib Hydrochloride [jan]

    42. Akos015958593

    43. Bcp9001052

    44. Ccg-269485

    45. Cs-0126

    46. Gsk-786034

    47. Ks-1458

    48. Nsc-737754

    49. Pazopanib Hydrochloride [mart.]

    50. Pb31655

    51. Sb10367

    52. Pazopanib Hydrochloride [who-dd]

    53. Ac-24726

    54. Bp166746

    55. Hy-12009

    56. Smr003500790

    57. Am20090655

    58. Ft-0687642

    59. P2243

    60. Pazopanib Hydrochloride [orange Book]

    61. Sw218082-2

    62. Ec-000.2347

    63. D05380

    64. A834417

    65. Q27888072

    66. 5-({4-[(2,3-dimethyl-2h-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide Hydrochloride

    67. 5-(4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide Hydrochloride

    68. 5-(4-((2,3-dimethyl-2h-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide Hydrochloride;5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide Hydrochloride

    69. 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride

    70. Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, Hydrochloride (1:1)

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 474.0 g/mol
    Molecular Formula C21H24ClN7O2S
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count5
    Exact Mass473.1400719 g/mol
    Monoisotopic Mass473.1400719 g/mol
    Topological Polar Surface Area127 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity717
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameVotrient
    PubMed HealthPazopanib (By mouth)
    Drug ClassesAntineoplastic Agent, Immunological Agent
    Active IngredientPazopanib hydrochloride
    Dosage FormTablet
    RouteOral
    Strengtheq 200mg base; eq 400mg base
    Market StatusPrescription
    CompanyGlaxosmithkline

    2 of 2  
    Drug NameVotrient
    PubMed HealthPazopanib (By mouth)
    Drug ClassesAntineoplastic Agent, Immunological Agent
    Active IngredientPazopanib hydrochloride
    Dosage FormTablet
    RouteOral
    Strengtheq 200mg base; eq 400mg base
    Market StatusPrescription
    CompanyGlaxosmithkline

    4.2 Drug Indication

    * Renal-cell carcinoma (RCC):

    Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.

    * Soft-tissue sarcoma (STS):

    Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.

    Efficacy and safety have only been established in certain STS histological tumour subtypes.

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Pharmacological Classes
    Cytochrome P450 2D6 Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]; Cytochrome P450 2C8 Inhibitors [MoA]
    5.2 ATC Code

    L01XE11

    Post Enquiry
    POST ENQUIRY